var data={"title":"Ethambutol: An overview","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Ethambutol: An overview</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/ethambutol-an-overview/contributors\" class=\"contributor contributor_credentials\">Richard H Drew, PharmD, MS, FCCP, FIDP</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/ethambutol-an-overview/contributors\" class=\"contributor contributor_credentials\">Stephen B Calderwood, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/ethambutol-an-overview/contributors\" class=\"contributor contributor_credentials\">Elinor L Baron, MD, DTMH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/ethambutol-an-overview/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Nov 07, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">Ethambutol</a> is an antimycobacterial agent that is most commonly used in combination with other drugs in the treatment of tuberculosis [<a href=\"https://www.uptodate.com/contents/ethambutol-an-overview/abstract/1\" class=\"abstract_t\">1</a>]. It is also used as part of a combination regimen in the therapy of <em>Mycobacterium avium</em> complex (MAC) infections in patients with or without concomitant infection with human immunodeficiency virus (HIV) [<a href=\"https://www.uptodate.com/contents/ethambutol-an-overview/abstract/1\" class=\"abstract_t\">1</a>].</p><p>The American Thoracic Society (ATS), United States Centers for Disease Control and Prevention (CDC), and Infectious Disease Society of America (IDSA) statement on the treatment of tuberculosis, as well as other ATS guidelines, can be accessed through the <a href=\"http://www.thoracic.org/statements/&amp;token=qarzLAn4JdAbZ323FG1scHYDG28iQPBGI48zV/nNgikyfVut82/f14D/ERhZjGMy&amp;TOPIC_ID=478\" target=\"_blank\" class=\"external\">ATS website</a>.</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">MECHANISM OF ACTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The mechanism of action of <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a> is not completely known. There is evidence that the drug exerts its bacteriostatic activity by virtue of inhibition of arabinosyl transferase, an enzyme that polymerizes arabinose into arabinan and then arabinogalactan, a mycobacterial cell wall constituent.</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">RESISTANCE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Organisms with minimum inhibitory concentrations exceeding 5 <span class=\"nowrap\">mcg/mL</span> are generally considered resistant to <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a>. <em>M. tuberculosis</em> resistance to ethambutol is due to random spontaneous genetic mutations, occurring at a rate of approximately 1 in 10<sup>7</sup> organisms. Mutations most commonly result in increased production of the enzyme arabinosyl transferase, which overwhelms the inhibitory effects of ethambutol [<a href=\"https://www.uptodate.com/contents/ethambutol-an-overview/abstract/2,3\" class=\"abstract_t\">2,3</a>]. (See <a href=\"topic.htm?path=epidemiology-and-molecular-mechanisms-of-drug-resistant-tuberculosis\" class=\"medical medical_review\">&quot;Epidemiology and molecular mechanisms of drug-resistant tuberculosis&quot;</a>.)</p><p>Primary (pretreatment) resistance rates of <em>M. tuberculosis</em> to <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a> vary widely. Although a report from New York City cited primary resistance as high as 14 percent, a global survey performed in 35 countries between 1994 and 1997 found a primary ethambutol resistance rate of 1 percent [<a href=\"https://www.uptodate.com/contents/ethambutol-an-overview/abstract/4\" class=\"abstract_t\">4</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">SPECTRUM OF ACTIVITY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The antimicrobial activity of <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a> is limited to mycobacteria. Most data regarding the clinical and in vitro activity of ethambutol derive from experience with the drug in patients with tuberculosis. Minimum inhibitory concentrations for <em>M. tuberculosis</em> range between 1 and 5 <span class=\"nowrap\">microgram/mL</span> [<a href=\"https://www.uptodate.com/contents/ethambutol-an-overview/abstract/5\" class=\"abstract_t\">5</a>]. Synergy of ethambutol against <em>M. tuberculosis</em> has been demonstrated in some in vitro models with other antimycobacterial drugs, such as <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> and fluoroquinolones.</p><p><a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">Ethambutol</a> has variable activity against nontuberculous mycobacteria:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>M. bovis</em> and <em>M. kansasii </em>are usually inhibited by <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a> concentrations that are achievable in the blood.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>M. avium</em> complex (MAC) is also generally susceptible but may require higher concentrations (up to 10 <span class=\"nowrap\">microgram/mL)</span>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>M. fortuitum</em> and <em>M. chelonae </em>are often highly resistant to <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a>.</p><p/><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">PHARMACOKINETICS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Approximately 80 percent of an <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a> dose is absorbed after oral administration; absorption is not significantly altered by food but is reduced by concomitant ingestion of <a href=\"topic.htm?path=aluminum-hydroxide-drug-information\" class=\"drug drug_general\">aluminum hydroxide</a>. Peak serum levels after repeated doses of 25 <span class=\"nowrap\">mg/kg</span> are approximately 4 to 5 <span class=\"nowrap\">microgram/mL</span> and occur between two and four hours after administration.</p><p>Because of its low degree of protein binding (6 to 30 percent), <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a> undergoes wide distribution. However, cerebrospinal concentrations are low (1 to 2 <span class=\"nowrap\">microgram/mL)</span> in the absence of inflamed meninges. Ethambutol is partially metabolized in the liver, with 50 to 80 percent of the drug excreted unchanged in the urine and 20 percent in the feces. The serum half-life of 2.5 to 3.6 hours may be prolonged to up to 10 hours in patients with end-stage renal disease, requiring dose adjustment (<a href=\"image.htm?imageKey=ID%2F63357\" class=\"graphic graphic_table graphicRef63357 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/ethambutol-an-overview/abstract/6\" class=\"abstract_t\">6</a>].</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">DOSING AND ADMINISTRATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">Ethambutol</a> tablets are available in strengths of 100 and 400 mg. The dose of ethambutol is dependent upon body weight, frequency of administration, and indication.</p><p>For the treatment of tuberculosis, the recommended daily dose of <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a> in children is 15 to 20 <span class=\"nowrap\">mg/kg</span> per day (maximum dose 1.0 g) or 50 <span class=\"nowrap\">mg/kg</span> twice weekly (maximum dose 2.5 g) in combination with other antimycobacterial agents. In order to use whole tablets, weight-based recommendations (based on lean body weight) have been established for adults (<a href=\"image.htm?imageKey=PULM%2F71883\" class=\"graphic graphic_table graphicRef71883 \">table 2</a>). Alternate dosing guidelines are not available; data obtained in children suggest the need for higher doses to obtain target peak plasma concentrations [<a href=\"https://www.uptodate.com/contents/ethambutol-an-overview/abstract/7\" class=\"abstract_t\">7</a>].</p><p>HIV-infected patients treated for <em>M. avium</em> complex (MAC) are usually given 15 <span class=\"nowrap\">mg/kg</span> once daily. HIV-uninfected patients with MAC pulmonary infection are usually treated with 25 <span class=\"nowrap\">mg/kg</span> per day for the first two months followed by 15 <span class=\"nowrap\">mg/kg</span> per day. (See <a href=\"topic.htm?path=mycobacterium-avium-complex-mac-infections-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;Mycobacterium avium complex (MAC) infections in HIV-infected patients&quot;</a> and <a href=\"topic.htm?path=treatment-of-mycobacterium-avium-complex-lung-infection-in-adults\" class=\"medical medical_review\">&quot;Treatment of Mycobacterium avium complex lung infection in adults&quot;</a>.)</p><p>Alternate antituberculosis regimens with <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a> include daily therapy for the first two weeks, then two or three times weekly. Ethambutol may be discontinued prior to eight weeks if the organism is susceptible to <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> (INH) and <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>, but rifampin-monoresistant strains may require treatment with INH and ethambutol for 18 months. (See <a href=\"topic.htm?path=treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults\" class=\"medical medical_review\">&quot;Treatment of drug-resistant pulmonary tuberculosis in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">SPECIAL POPULATIONS</span></p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Liver failure</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>No adjustment of the <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a> dose is necessary in patients with hepatic failure.</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Renal insufficiency</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with creatinine clearances between 30 and 50 <span class=\"nowrap\">mL/minute,</span> the dosing interval for <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a> should be extended from 24 to 36 hours. Patients with creatinine clearance less than 30 <span class=\"nowrap\">mL/minute</span> or requiring dialysis should receive a dose of 15 to 20 <span class=\"nowrap\">mg/kg</span> three times weekly by directly observed therapy.</p><p>Those requiring hemodialysis should receive the dose after dialysis. A report of a patient undergoing high-flux hemodialysis reported a mean 41 percent decrease in serum <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a> concentration during dialysis [<a href=\"https://www.uptodate.com/contents/ethambutol-an-overview/abstract/8\" class=\"abstract_t\">8</a>].</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Children</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Since visual acuity and color perception changes are difficult to assess in young patients, <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a> is usually avoided in children whose visual acuity cannot be accurately assessed, except in cases of drug resistance or in special situations where the disease is &quot;adult type&quot; (ie, upper lobe, cavitating lesions). However, the magnitude of risk posed by ethambutol in this setting is debated [<a href=\"https://www.uptodate.com/contents/ethambutol-an-overview/abstract/9\" class=\"abstract_t\">9</a>].</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Pregnancy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">Ethambutol</a> is generally considered safe during pregnancy. (See <a href=\"topic.htm?path=tuberculosis-in-pregnancy\" class=\"medical medical_review\">&quot;Tuberculosis in pregnancy&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Older adults</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Older adult patients may be more susceptible to the side effects of <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a>, especially if they are receiving higher doses. Since renal function declines with age, careful attention should be paid to the need for potential dose adjustment based upon renal function in this patient population.</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">HIV-infected patients</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>HIV patients receiving <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a> in combination with <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> frequently demonstrate low maximum serum concentrations (observed with a daily dose of 20 <span class=\"nowrap\">mg/kg</span> or 50 <span class=\"nowrap\">mg/kg</span> twice weekly or 30 <span class=\"nowrap\">mg/kg</span> thrice weekly) [<a href=\"https://www.uptodate.com/contents/ethambutol-an-overview/abstract/10\" class=\"abstract_t\">10</a>].</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h1\">ADVERSE REACTIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">Ethambutol</a> is generally well tolerated. Side effects are usually dose related and are more common when doses exceed 15 <span class=\"nowrap\">mg/kg</span>.</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Visual changes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Optic neuropathy (usually manifested as a change in visual acuity or red-green color blindness) is the most important <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a> toxicity. The reported incidence of optic neuropathy when ethambutol is taken for more than two months is 18 percent in subjects receiving more than 35 <span class=\"nowrap\">mg/kg</span> per day, 5 to 6 percent with 25 <span class=\"nowrap\">mg/kg</span> per day, and less than 1 percent with 15 <span class=\"nowrap\">mg/kg</span> per day [<a href=\"https://www.uptodate.com/contents/ethambutol-an-overview/abstract/11\" class=\"abstract_t\">11</a>]. Optic neuritis is reversible in most patients.</p><p>Intermittent <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a> dosing may decrease the risk of ocular toxicity as illustrated in a study of 229 patients treated with ethambutol for pulmonary <em>M. avium</em> complex (MAC) disease [<a href=\"https://www.uptodate.com/contents/ethambutol-an-overview/abstract/12\" class=\"abstract_t\">12</a>]. The incidence of ocular toxicity, confirmed by an ophthalmologist, in those treated with daily ethambutol (25 <span class=\"nowrap\">mg/kg</span> per day for two months, then 15 <span class=\"nowrap\">mg/kg</span> per day) compared to intermittent therapy (25 <span class=\"nowrap\">mg/kg</span> three days a week) was 6 versus 0 percent, respectively.</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Other reactions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hematologic (neutropenia, thrombocytopenia), gastrointestinal (nausea, vomiting, abdominal pain, hepatotoxicity), central nervous system (headache, dizziness, confusion), and cutaneous reactions occur infrequently but may be more common in patients receiving concomitant <a href=\"topic.htm?path=ethionamide-drug-information\" class=\"drug drug_general\">ethionamide</a> therapy.</p><p><a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">Ethambutol</a>, when used in combination with <a href=\"topic.htm?path=pyrazinamide-drug-information\" class=\"drug drug_general\">pyrazinamide</a> for the treatment of latent tuberculosis in patients exposed to multidrug-resistant strains, has been associated with a high incidence of hepatotoxicity or gastrointestinal intolerance leading to discontinuation of therapy (approximately 60 percent of treated subjects in one report) [<a href=\"https://www.uptodate.com/contents/ethambutol-an-overview/abstract/13\" class=\"abstract_t\">13</a>].</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h2\">Monitoring</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>It is generally recommended that patients receiving <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a> as part of combination therapy for treatment of a mycobacterial infection undergo baseline Snellen visual acuity and red-green color perception testing. All patients should be advised of the side effects associated with ethambutol, most notably those associated with the development of optic neuritis. The need for routine periodic visual acuity testing during therapy is controversial, especially if a dose of 15 <span class=\"nowrap\">mg/kg</span> is chosen, but patients noting changes in their vision should be referred to an ophthalmologist for careful monitoring. In all patients receiving combination therapy for tuberculosis or MAC infections, baseline laboratory studies should be obtained and repeated in the event of suspected drug-related toxicity.</p><p>Although serum concentration monitoring of <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a> is not routinely performed, it may be useful in cases of severe renal insufficiency or suspected malabsorption (as demonstrated in some HIV-infected patients receiving antituberculous therapy) (see <a href=\"#H13\" class=\"local\">'HIV-infected patients'</a> above). If serum drug level monitoring is performed, the proposed therapeutic range two hours post-dose is 2 to 6 <span class=\"nowrap\">mcg/mL</span>.</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h1\">DRUG INTERACTIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Detail about specific interactions is available by using the Lexi-Interact program included with UpToDate.</p><p class=\"headingAnchor\" id=\"H1564659\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">Ethambutol</a> is an antimycobacterial agent that is most commonly used in combination with other drugs in the treatment of tuberculosis. It is also used as part of a combination regimen in the therapy of <em>Mycobacterium avium</em> complex (MAC) infections in patients with or without concomitant infection with human immunodeficiency virus (HIV). (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The mechanism of action of <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a> is not completely understood. There is evidence that ethambutol exerts its bacteriostatic activity through inhibition of arabinosyl transferase, an enzyme that plays an important role in mycobacterial cell wall formation. (See <a href=\"#H2\" class=\"local\">'Mechanism of action'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Organisms with a minimal inhibitory concentration exceeding 5 <span class=\"nowrap\">mcg/mL</span> are generally considered resistant to <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a>. (See <a href=\"#H3\" class=\"local\">'Resistance'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The antimicrobial activity of <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a> is limited to mycobacteria. Synergy of ethambutol with other antimycobacterial drugs, such as <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> and fluoroquinolones, has been demonstrated in vitro against <em>M. tuberculosis</em>. Ethambutol has variable activity against nontuberculous mycobacteria. (See <a href=\"#H4\" class=\"local\">'Spectrum of activity'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">Ethambutol</a> is well absorbed after oral administration. Because of its low degree of protein binding, ethambutol undergoes wide distribution. However, cerebrospinal concentrations are low in the absence of inflamed meninges. (See <a href=\"#H5\" class=\"local\">'Pharmacokinetics'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The dose of <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a> is dependent upon body weight, frequency of administration, and indication. (See <a href=\"#H6\" class=\"local\">'Dosing and administration'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>No adjustment of the <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a> dose is necessary in patients with hepatic failure. For patients with creatinine clearances between 30 and 50 <span class=\"nowrap\">mL/min,</span> the dosing interval for ethambutol should be extended from 24 to 36 hours. A small amount of ethambutol is removed by hemodialysis. (See <a href=\"#H7\" class=\"local\">'Special populations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">Ethambutol</a> is generally considered safe during pregnancy. (See <a href=\"#H11\" class=\"local\">'Pregnancy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Optic neuropathy (usually manifested as a change in visual acuity or red-green color blindness) is the most important <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a> toxicity. The reported incidence of optic neuropathy when ethambutol is taken for more than two months increases with higher dosing of the drug. Optic neuritis is reversible in most patients. (See <a href=\"#H15\" class=\"local\">'Visual changes'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>It is generally recommended that patients receiving <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a> as part of combination therapy for treatment of a mycobacterial infection undergo baseline Snellen visual acuity and red-green color perception testing. (See <a href=\"#H17\" class=\"local\">'Monitoring'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li class=\"breakAll\">Lewis ML. Ethambutol. In: Antimicrobial Therapy and Vaccines, Yu V, Merigan T, Barriere S (Eds), Williams &amp; Wilkins, Baltimore 1998.</li><li><a href=\"https://www.uptodate.com/contents/ethambutol-an-overview/abstract/2\" class=\"nounderline abstract_t\">Telenti A, Philipp WJ, Sreevatsan S, et al. The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nat Med 1997; 3:567.</a></li><li><a href=\"https://www.uptodate.com/contents/ethambutol-an-overview/abstract/3\" class=\"nounderline abstract_t\">Belanger AE, Besra GS, Ford ME, et al. The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc Natl Acad Sci U S A 1996; 93:11919.</a></li><li><a href=\"https://www.uptodate.com/contents/ethambutol-an-overview/abstract/4\" class=\"nounderline abstract_t\">Pablos-M&eacute;ndez A, Raviglione MC, Laszlo A, et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 1998; 338:1641.</a></li><li><a href=\"https://www.uptodate.com/contents/ethambutol-an-overview/abstract/5\" class=\"nounderline abstract_t\">Karlson AG. The in vitro activity of ethambutol (dextro2,2[ethylenediimino]di-1-butanol) against tubercle bacilli and other microorganisms. Am Rev Resp Dis 1961; 83:905.</a></li><li><a href=\"https://www.uptodate.com/contents/ethambutol-an-overview/abstract/6\" class=\"nounderline abstract_t\">Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63:e147.</a></li><li><a href=\"https://www.uptodate.com/contents/ethambutol-an-overview/abstract/7\" class=\"nounderline abstract_t\">Yang H, Enimil A, Gillani FS, et al. Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children: Adequacy of Revised Dosages of TB Drugs for Children. Pediatr Infect Dis J 2018; 37:43.</a></li><li><a href=\"https://www.uptodate.com/contents/ethambutol-an-overview/abstract/8\" class=\"nounderline abstract_t\">Chew R, Jongbloed S, Jegatheesan D, et al. Ethambutol Is Cleared by a Contemporary High-Flux Hemodialyzer, and Drug Monitoring Ensures Safety and Therapeutic Effect. Antimicrob Agents Chemother 2017; 61.</a></li><li><a href=\"https://www.uptodate.com/contents/ethambutol-an-overview/abstract/9\" class=\"nounderline abstract_t\">Tr&eacute;bucq A. Should ethambutol be recommended for routine treatment of tuberculosis in children? A review of the literature. Int J Tuberc Lung Dis 1997; 1:12.</a></li><li><a href=\"https://www.uptodate.com/contents/ethambutol-an-overview/abstract/10\" class=\"nounderline abstract_t\">Perlman DC, Segal Y, Rosenkranz S, et al. The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. Clin Infect Dis 2005; 41:1638.</a></li><li><a href=\"https://www.uptodate.com/contents/ethambutol-an-overview/abstract/11\" class=\"nounderline abstract_t\">Leibold JE. The ocular toxicity of ethambutol and its relation to dose. Ann N Y Acad Sci 1966; 135:904.</a></li><li><a href=\"https://www.uptodate.com/contents/ethambutol-an-overview/abstract/12\" class=\"nounderline abstract_t\">Griffith DE, Brown-Elliott BA, Shepherd S, et al. Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2005; 172:250.</a></li><li><a href=\"https://www.uptodate.com/contents/ethambutol-an-overview/abstract/13\" class=\"nounderline abstract_t\">Younossian AB, Rochat T, Ketterer JP, et al. High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis. Eur Respir J 2005; 26:462.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 478 Version 15.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H1564659\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">MECHANISM OF ACTION</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">RESISTANCE</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">SPECTRUM OF ACTIVITY</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">PHARMACOKINETICS</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">DOSING AND ADMINISTRATION</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">SPECIAL POPULATIONS</a><ul><li><a href=\"#H8\" id=\"outline-link-H8\">Liver failure</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Renal insufficiency</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Children</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">Pregnancy</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">Older adults</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">HIV-infected patients</a></li></ul></li><li><a href=\"#H14\" id=\"outline-link-H14\">ADVERSE REACTIONS</a><ul><li><a href=\"#H15\" id=\"outline-link-H15\">Visual changes</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">Other reactions</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">Monitoring</a></li></ul></li><li><a href=\"#H18\" id=\"outline-link-H18\">DRUG INTERACTIONS</a></li><li><a href=\"#H1564659\" id=\"outline-link-H1564659\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/478|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ID/63357\" class=\"graphic graphic_table\">- Renal dosing of antituberculous agents</a></li><li><a href=\"image.htm?imageKey=PULM/71883\" class=\"graphic graphic_table\">- Ethambutol dosing</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-and-molecular-mechanisms-of-drug-resistant-tuberculosis\" class=\"medical medical_review\">Epidemiology and molecular mechanisms of drug-resistant tuberculosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=mycobacterium-avium-complex-mac-infections-in-hiv-infected-patients\" class=\"medical medical_review\">Mycobacterium avium complex (MAC) infections in HIV-infected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-mycobacterium-avium-complex-lung-infection-in-adults\" class=\"medical medical_review\">Treatment of Mycobacterium avium complex lung infection in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults\" class=\"medical medical_review\">Treatment of drug-resistant pulmonary tuberculosis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tuberculosis-in-pregnancy\" class=\"medical medical_review\">Tuberculosis in pregnancy</a></li></ul></div></div>","javascript":null}